3 New Strong Buy Ratings from Top-Rated Analysts: 08/22/2025
Ease into the weekend with 3 hot picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Pagaya Technologies (PGY) may be at the perfect entry point RN, according to experts
- Neurocrine Biosciences ( NBIX) appears to be trading at a very attractive valuation
- Why Udemy (UDMY) is an under-$10 winner worth watching
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
What are the "Double Engine" stocks for 2025? Instead of settling for income or growth, these are stocks that deliver both. Our 10 Best Stocks to Own: Fall 2025 report includes companies that are the perfect combination of steady payouts and explosive capital appreciation potential - all in one portfolio-ready list. This is how you position ahead of a market tailwind. Access the list now while it's still free - because once the rally is in motion, you'll be chasing instead of leading.
1. Neurocrine Biosciences (NASDAQ: NBIX)
Neurocrine Biosciences is a neuroscience-focused biopharma business that maintains a growing drug pipeline targeting movement disorders, epilepsy, depression, and rare pediatric diseases. The company recently delivered a double beat, and Wall Street’s expectations are rather high — however, NBIX is still trading at a very attractive valuation.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $134.49 — get current quote >
Max 1-year forecast: $185.00
Why we’re watching:
- Neurocrine Biosciences enjoys broad analyst support — the stock has 8 Strong Buy ratings, 5 Buy ratings, and 2 Hold ratings. See the ratings
- The average price target for NBIX shares, currently pegged at $159.87, implies a 19.99% upside.
- Guggenheim researcher Yatin Suneja (a top 18% rated analyst) maintained a Strong Buy rating on the stock following the company’s Q2 2025 earnings and hiked his price target from $165 to $175.
- Suneja told readers that the quarter's adjusted EPS beat consensus and management narrowed its FY 2025 Ingrezza revenue guidance to $2.5B to $2.55B.
- The next key catalysts for the stock will be the Phase 2 readout in MDD with NBI-770 and Phase 3 readouts in Dyskinetic Cerebral Palsy, both due in Q4, the analyst added.
- NBIX is the 7th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
- Neurocrine Biosciences shares rank in the top 3% of the equities that we track, giving them a Zen Rating of A.
- NBIX is currently trading at quite an attractive valuation — in terms of its Value Component Grade rating, the stock ranks in the top 8% of equities.
- NBIX ranks even more highly when it comes to Financials and Artificial Intelligence — in both cases, the stock is in the 96th percentile. (See all 7 Zen Component Grades here >)
2. Pagaya Technologies (NASDAQ: PGY)
Pagaya Technologies uses artificial intelligence to expand access to consumer credit. The company partners with banks, fintechs, and auto lenders to provide capital and analytics that help underwrite loans for underserved borrowers. While the business missed EPS estimates in its last quarterly report, long-term growth prospects remain fantastic — and the stock price has dropped by 10.6% in the past week, so we have a great opportunity to buy the dip on our hands here.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $30.07 — get current quote >
Max 1-year forecast: $54.00
Why we’re watching:
- At present, PGY shares are tracked by 7 Wall Street analysts — their coverage is split between 4 Strong Buy ratings and 3 Buy ratings. See the ratings
- In addition, the average 12-month price forecast for Pagaya Technologies stock, currently pegged at $39.43, implies a hefty 30.17% upside.
- B. Riley Securities researcher Hal Goetsch (a top 2% rated analyst) reiterated a Strong Buy rating on the stock after Pagaya Technologies reported its Q2 2025 earnings, and increased his price target from $46 to a Street-high $54.
- Goetsch attributed their hiked EPS estimates for this year and FY 2026 to the quarter's beat and management's guidance raise.
- PGY is the 7th highest-rated stock in the Software Infrastructure industry, which has an Industry Rating of A.
- Pagaya Technologies shares rank in the top 5% of the equities that we track, giving them a Zen Rating of A. Stocks with this distinction have provided an average annual return of 32.52% since the turn of the millennium — interestingly enough, that figure lines up fairly decently with Wall Street’s expectations.
- A neural network trained on two decades of fundamental and technical data has pinpointed PGY as a likely outperformer — the stock ranks in the top 4% of equities in terms of its Artificial Intelligence rating.
- However, Growth is the star of the show here — Pagaya Technologies ranks in the top 1% of stocks in this regard. (See all 7 Zen Component Grades here >)
A note from our sponsors...
3. Udemy (NASDAQ: UDMY)
This pick is also our latest Stock of the Week. Udemy is known far and wide as the premier online platform for taking courses and mastering new skills. With the advent of AI, the job market is poised for major changes — and UDMY is well-positioned to benefit, having recently announced a deal with online jobs site Indeed. To further sweeten the pot, the stock is incredibly well-rounded.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $6.77 — get current quote >
Max 1-year forecast: $12.00
Why we’re watching:
- UDMY is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained why he added it to his exclusive Zen Investor portfolio in a Monday article. We’ll go through some of the most important points below.
- This stock has been working off the excesses from its overhyped IPO back in late 2021 when it sprung to over $30 per share. Since then, UDMY has produced 14 impressive beat and raise earnings reports and yet still shares have slunk down to under $7 today.
- Udemy is also one of the top 7 stocks under $10 — which has earned it a spot in our Stocks under $10 strategy.
- Next year’s earnings estimates stand at 55 cents — however, in the past three quarters, the business has delivered an average EPS beat of 35%.
- Steve believes that the UDMY could surge to levels as high as $14 in 2026.
- Wall Street analysts agree with our Editor-in-Chief — the average price target for UDMY shares currently stands at $9.71, and implies a 44.77% upside. Udemy currently has 2 Strong Buy ratings, 2 Buy ratings, and 3 Hold ratings.
- UDMY ranks in the top 2% of the more than 4,600 stocks that we track, giving it a Zen Rating of A.
- Udemy is also currently the top-rated stock in the Education industry, which has an Industry Rating of A.
- UDMY is an incredibly well-rounded stock — it ranks in the top 19% in terms of Value, the top 13% when it comes to Sentiment, and the top 12% when looking at Financials.
- That isn’t the end of it, however, as Udemy shares also rank in the 91st percentile according to Growth and the 92nd percentile according to Artificial Intelligence. (See all 7 Zen Component Grades here >)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.